Synergistic effect of ibrutinib and CD19 CAR‐T cells on Raji cells in vivo and in vitro

Ibrutinib might improve the efficacy of anti‐CD19 chimeric antigen receptor (CD19 CAR) T‐cell therapy in chronic lymphocytic leukemia (CLL). We studied the possibility and mechanism of the synergistic effect of ibrutinib and CAR‐T cells in other types of lymphoma. In this study, we selected the CD19...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Meijing, Wang, Xuelin, Li, Zheng, Zhang, Rui, Mu, Juan, Jiang, Yanyu, Deng, Qi, Sun, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648031/
https://www.ncbi.nlm.nih.gov/pubmed/32876369
http://dx.doi.org/10.1111/cas.14638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648031/
https://www.ncbi.nlm.nih.gov/pubmed/32876369
http://dx.doi.org/10.1111/cas.14638

Ejemplares similares